Sitagliptin - Enhancing incretin action

Ian W. Campbell; Caroline Day

doi:10.1177/14746514070070030601

Sitagliptin - Enhancing incretin action

Ian W. Campbell, Caroline Day^*

^*Corresponding author for this work

College of Health and Life Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.

Original language	English
Pages (from-to)	134-139
Number of pages	6
Journal	British Journal of Diabetes and Vascular Disease
Volume	7
Issue number	3
DOIs	https://doi.org/10.1177/14746514070070030601
Publication status	Published - 1 May 2007

Keywords

DPP-4
Gliptin
Incretin
Inhibitor
Sitagliptin
Type 2 diabetes

Access to Document

10.1177/14746514070070030601

Cite this

@article{9eb2b4ad0b43431f90101b7d3fc24904,

title = "Sitagliptin - Enhancing incretin action",

abstract = "DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.",

keywords = "DPP-4, Gliptin, Incretin, Inhibitor, Sitagliptin, Type 2 diabetes",

author = "Campbell, {Ian W.} and Caroline Day",

year = "2007",

month = may,

day = "1",

doi = "10.1177/14746514070070030601",

language = "English",

volume = "7",

pages = "134--139",

journal = "British Journal of Diabetes and Vascular Disease",

issn = "1474-6514",

publisher = "SAGE",

number = "3",

}

TY - JOUR

T1 - Sitagliptin - Enhancing incretin action

AU - Campbell, Ian W.

AU - Day, Caroline

PY - 2007/5/1

Y1 - 2007/5/1

N2 - DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.

AB - DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.

KW - DPP-4

KW - Gliptin

KW - Incretin

KW - Inhibitor

KW - Sitagliptin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=34547799011&partnerID=8YFLogxK

U2 - 10.1177/14746514070070030601

DO - 10.1177/14746514070070030601

M3 - Article

AN - SCOPUS:34547799011

SN - 1474-6514

VL - 7

SP - 134

EP - 139

JO - British Journal of Diabetes and Vascular Disease

JF - British Journal of Diabetes and Vascular Disease

IS - 3

ER -

Sitagliptin - Enhancing incretin action

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this